Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
life sciences
national blog main
10
×
national top stories
novartis
10
×
boston blog main
boston top stories
new york top stories
san francisco top stories
indiana blog main
indiana top stories
national
new york blog main
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
cancer
clinical trials
deals
drug prices
eli lilly
medicare
merck
pfizer
roche
abbvie
alzheimer's disease
What
drug
10
×
bio
new
roundup
fda
approval
medicines
patients
acquisitions
biggest
brings
ceo
companies
company
latest
pharmaceutical
plan
price
prices
therapy
today
acquire
address
advantages
agreed
albert
alzheimer’s
amgen
approved
approves
atrophy
away
bar
billion
biogen’s
biopharmaceutical
blueprint
bourla
bringing
build
Language
unset
unknown
Current search:
drug
×
biotech
×
novartis
×
" national blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines